François Cherbonneau
CEO
QUIDDITAS
The company develops genome editing-based therapies for genetic disorders, oncology, and organ transplants. Their technology enables precise genetic recombination to create off-the-shelf treatments for previously incurable diseases.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Existing genome editing tools face limitations in standardization, efficiency, specificity, and the size of DNA recombination, hindering their widespread application in treating genetic diseases and other biotechnological applications. These challenges restrict the ability to make large, targeted genetic changes necessary for addressing complex and rare conditions.
Solution
Quidditas Therapeutics has developed the GREAT (Gene REcombination Along with Transposase) technology, a novel genome editing platform designed to overcome the limitations of existing tools. GREAT enables precise and controlled excision and insertion of nucleic acid sequences of any length, whether RNA or DNA, at any location in the genome. This technology facilitates complete gene or exon replacement, bypassing technical constraints associated with other methods like CRISPR-Cas9. The platform's guided transposon-based approach allows for efficient and scalable DNA integration and recombination, expanding the possibilities for gene therapy, bioprocess improvement, and synthetic biology.
Target Audience
Quidditas Therapeutics primarily targets pharmaceutical and biotech companies seeking innovative genome editing tools for therapeutic development and bioprocess optimization, as well as researchers in gene therapy, synthetic biology, and biotechnology.
Features
- Targets and cuts single or double-stranded nucleic acid sequences (RNA or DNA)
- Pastes nucleic acids of any length at any location in the genome in a controlled manner
- Facilitates replacement of a full gene or exon by excising a selected sequence and adding a new double-stranded sequence
- Guided transposon-based approach for precise, efficient, and scalable DNA integration and recombination
- Applicable to genetic disorders, oncology, organ transplant, environment, and food industry
- Can be used as a bioprocess booster for routine research applications